Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9% - Should You Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price rose 7.9% on Friday . The company traded as high as $22.32 and last traded at $22.06. Approximately 172,474 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 407,259 shares. The stock had previously closed at $20.44.

Analysts Set New Price Targets

BCAX has been the topic of several research reports. Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an "overweight" rating on the stock. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating on the stock. Morgan Stanley started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating and a $47.00 price target on the stock.

Bicara Therapeutics Price Performance

Insider Activity at Bicara Therapeutics

In related news, major shareholder James E. Flynn acquired 70,000 shares of the business's stock in a transaction on Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now owns 897,587 shares in the company, valued at $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, major shareholder James E. Flynn acquired 70,000 shares of the company's stock in a transaction dated Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,833,000 shares of the business's stock in a transaction dated Monday, September 16th. The stock was purchased at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares of the company's stock, valued at $77,461,524. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.